Correlation between Interleukin-4 Gene Promoter Polymorphisms with Thyrotropin Receptor Antibody and Transforming Growth Factor-β

Raveinal Raveinal; Eryati Darwin; Eva Decroli; Jamsari Jamsari

doi:10.3889/oamjms.2020.5384

Authors

Raveinal Raveinal Department of Internal Medicine, Allergic and Imunology Subdivision, Dr. M. Djamil General Hospital, Faculty of Medicine, Andalas University, Padang, Indonesia
Eryati Darwin Department of Histology and Immunology, Faculty of Medicine, Andalas University, Padang, Indonesia
Eva Decroli Department of Internal Medicine, Endocrinology and Metabolic Subdivision, Dr. M. Djamil General Hospital, Faculty of Medicine, Andalas University, Padang, Indonesia
Jamsari Jamsari Department of Agriculture, Faculty of Agriculture, Andalas University, Padang, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.5384

Keywords:

Graves' disease, Interleukin-4, Gene promoter polymorphism, TRAb, TGF-β

Abstract

AIM: The aim of this study was to determine the correlation between interleukin-4 (IL-4) gene promoter polymorphisms with thyrotropin receptor antibody (TRAb) and transforming growth factor-β (TGF-β).

METHODS: This study was conducted from August 2015 until December 2015 in the internal medicine department in Dr. M. Djamil Hospital, Padang, West Sumatera, Indonesia. Graves’ disease was confirmed by measuring free thyroxine, thyroid-stimulating hormone, and TRAb. We examined that IL-4 promotor gene polymorphism was examined with a polymerase chain reaction. Graves’ disease serum patients will be used to check levels of TGFβ and TRAb antibodies using the enzyme-linked immunoassay method.

RESULTS: There are 15 patients in this study. The average of age in patients group is 40.87 (11.23) years. The number of female patients in this study is more than male patients, with the percentage of women are 73.3%, and men are 26.7%. The sequencing examination on IL-4 gene promoter resulted in 2 single nucleotide polymorphism motifs, which are rs2243250 and rs2070847. The mean TRAb level in wild type and mutant group is 6.77 (5.73) IU/L and 4.66 (3.91) IU/L, respectively. The mean TGF-β levels in wild type and mutant group are 1168.89 (438.91) pg/mL and 1114.79 (296.02) pg/mL, respectively. Statistical tests showed no association between IL-4 gene promoter polymorphisms with TRAb and TGF-β levels (p > 0.05).

CONCLUSION: There is no correlation between IL-4 gene promoter polymorphisms with TRAb and TGF-β.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Decroli E, Elvira D, Aprilia A. The profile of thyrotropin-releasing hormone, T-regulator, and interleukin-4 of untreated graves’ disease in Indonesia. Asian J Pharm Clin Res. 2020;13(7):57-9. https://doi.org/10.22159/ajpcr.2020.v13i7.37731

Davies T, Laurberg P, Bahn R. Hyperthyroid disorders. In: Melmed S, Polonsky K, Larsen R, Kronenberg H, editors. Williams Textbook of Endocrinology. 13th ed. Philadelphia, PA: Elsevier; 2011. p. 369-415.

Lillevang-Johansen M, Abrahamsen B, Jorgensen H, Brix T, Hegedus L. Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. J Clin Endocrinol Metab. 2017;102(7):2301-9. https://doi. org/10.1210/jc.2017-0016 PMid:28368540

Liu J, Fu J, Xu Y, Wang G. Antithyroid drug therapy for graves’ disease and implications for recurrence. Int J Endocrinol. 2017;2017:3813540. https://doi.org/10.1155/2017/3813540 PMid:28529524

The Indonesian Society of Endocrinology. Indonesian clinical practice guidelines for hyperthyroidism. J ASEAN Fed Endocr Soc. 2012;27(1):34-9. https://doi.org/10.15605/jafes.027.01.05

Wang PW, Chen IY, Juo SH, His E, Liu RT, Hsieh CJ. Genotype and phenotype predictors of relapse of graves’ disease after antithyroid drug withdrawal. Eur Thyroid J. 2012;1(4):251-8. https://doi.org/10.1159/00034262 PMid:24783027

Decroli E, Elvira D, Aprilia A. The effect of thionamide to TRH, TSH, IL-4, T-reg, and anti-TPO in graves’ disease. Indones J Pharm. 2019;30(2):122-7. https://doi.org/10.14499/ indonesianjpharm30iss2pp122-127

Decroli E, Manaf A, Syahbuddin S. Immunologic and hormonal effects of propylthiouracil treatment using maintenance dose in graves’ disease. Acta Med Indones. 2014;46(4):314-9. PMid:25633548

Elvira D, Darwin E. Role of pro-inflammatory and regulatory cytokines in pathogenesis of graves’ disease in association with autoantibody thyroid and regulatory FoxP3 T-cells. Int J Med Health Sci. 2017;11(3):69-72.

Elvira D. The role of T-regulatory expression in autoimmune thyroid disease and its association with thyroid antibody. J Autoimmune Dis. 2016;2(2):19. https://doi.org/10.21767/2471-8513.100019

Laurberg P, Nygaard B, Andersen S, Carle A, Karmisholt J, Kerjbjerg A, et al. Association between TSH-receptor autoimmunity, hyperthyroidism, goitre, and orbitopathy in 208 patients included in the remission induction and sustenance in graves’ disease study. J Thyroid Res. 2014;2014:165487. https://doi.org/10.1155/2014/165487 PMid:24696787

Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167-86. https://doi.org/10.1159/000490384 PMid:30283735

Boot C. Role of TSH Receptor antibodies in the diagnosis of graves’ disease. Clin Lab. 2016;2016:1-7.

Bell L, Hunter A, Kyriacou A, Mukherjee A, Syed A. Clinical diagnosis of graves’ or non-graves’ hyperthyroidism compared to TSH receptor antibody test. Endocr Connect. 2018;7(4):504-10. https://doi.org/10.1530/ec-18-0082 PMid:29531156

Ylli Z, Dyrmishi B, Puca E, Husi G, Kolici E, Kapia M, et al. TSH receptor antibody measurement in the diagnosis of graves’disease. Endocr Abstr. 2011;26:P433.

Chen X, Huang F, Qi Y, Zhou M, Yin Q, Peng Y, et al. Serum and thyroid level of let-7b and their correlation with TRAb in graves’ disease. J Transl Med. 2018;16(1):188-98. https://doi. org/10.1186/s12967-018-1565-9 PMid:29976201

Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JA, Welsh KI. Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab. 2000;85(5):1984-8. https://doi. org/10.1210/jcem.85.5.6588 PMid:10843185

Khalilzadeh O, Anvari M, Momen-Heravi F, Esteghamati A, Rashidi A, Mahmoudi M, et al. Gene polymorphisms of interleukin-4, interleukin-10 and transforming growth factor-beta in graves’ disease. Clin Exp Med. 2010;10(2):123-8. https://doi. org/10.1007/s10238-009-0078-5 PMid:19882211

Elvira D. Correlation between polymorphisms of foxp3 T-regulatory promotor gene with TGF-Β in patients with graves’ disease. Asian J Pharm Clin Res. 2020;13(7):133-5. https://doi. org/10.22159/ajpcr.2020.v13i7.37717

Kotajima N, Yanagawa Y, Aoki T, Tsunekawa K, Morimura T, Ogiwara T, et al. Influence of thyroid hormones and transforming growth factor-β1 on cystatin C concentration. J Int Med Res. 2010;38(4):1365-73. https://doi. org/10.1177/147323001003800418 PMid:20926009